Inovio Pharmaceuticals Inc (INO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inovio Pharmaceuticals Inc (INO) has a cash flow conversion efficiency ratio of 2.795x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.57 Million) by net assets ($-7.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Inovio Pharmaceuticals Inc's balance sheet to measure how much of total assets are equity-financed.
Inovio Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Inovio Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Inovio Pharmaceuticals Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Inovio Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inovio Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DSR Corp
KO:155660
|
0.038x |
|
Space Hellas SA
AT:SPACE
|
-0.583x |
|
Seres Therapeutics Inc
NASDAQ:MCRB
|
-0.617x |
|
Airmate Cayman International Co Ltd
TW:1626
|
-0.074x |
|
YATRA ONLINE DL-0001
F:26Y
|
N/A |
|
JR HOLDING SA BC ZY -10
F:8JA
|
0.002x |
|
Hoang Quan Consulting Trading Service Real Estate Corp
VN:HQC
|
0.115x |
|
Pharmx Technologies Ltd
AU:PHX
|
-0.559x |
Annual Cash Flow Conversion Efficiency for Inovio Pharmaceuticals Inc (1998–2024)
The table below shows the annual cash flow conversion efficiency of Inovio Pharmaceuticals Inc from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see Inovio Pharmaceuticals Inc (INO) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $68.50 Million | $-104.08 Million | -1.519x | -43.36% |
| 2023-12-31 | $117.35 Million | $-124.37 Million | -1.060x | -8.99% |
| 2022-12-31 | $222.36 Million | $-216.22 Million | -0.972x | -80.16% |
| 2021-12-31 | $399.67 Million | $-215.71 Million | -0.540x | -39.84% |
| 2020-12-31 | $461.14 Million | $-177.98 Million | -0.386x | +97.87% |
| 2019-12-31 | $5.40 Million | $-97.85 Million | -18.104x | -2042.27% |
| 2018-12-31 | $87.03 Million | $-73.55 Million | -0.845x | -90.50% |
| 2017-12-31 | $142.49 Million | $-63.21 Million | -0.444x | +12.51% |
| 2016-12-31 | $123.38 Million | $-62.56 Million | -0.507x | -617.11% |
| 2015-12-31 | $175.93 Million | $-12.44 Million | -0.071x | +73.56% |
| 2014-12-31 | $111.54 Million | $-29.82 Million | -0.267x | +8.04% |
| 2013-12-31 | $52.90 Million | $-15.38 Million | -0.291x | +54.57% |
| 2012-12-31 | $34.86 Million | $-22.31 Million | -0.640x | -55.04% |
| 2011-12-31 | $47.86 Million | $-19.76 Million | -0.413x | -62.86% |
| 2010-12-31 | $47.10 Million | $-11.94 Million | -0.253x | -10.13% |
| 2009-12-31 | $61.18 Million | $-14.08 Million | -0.230x | +60.48% |
| 2008-12-31 | $19.11 Million | $-11.13 Million | -0.582x | -56.97% |
| 2007-12-31 | $31.03 Million | $-11.51 Million | -0.371x | -23.80% |
| 2006-12-31 | $23.50 Million | $-7.04 Million | -0.300x | +42.99% |
| 2005-12-31 | $23.47 Million | $-12.34 Million | -0.526x | -20.20% |
| 2004-12-31 | $15.55 Million | $-6.80 Million | -0.437x | -139.45% |
| 2003-12-31 | $15.05 Million | $-2.75 Million | -0.183x | +86.28% |
| 2002-12-31 | $3.73 Million | $-4.96 Million | -1.331x | +21.06% |
| 2001-12-31 | $4.96 Million | $-8.37 Million | -1.687x | -89.75% |
| 2000-12-31 | $9.89 Million | $-8.79 Million | -0.889x | -66.92% |
| 1999-12-31 | $11.83 Million | $-6.30 Million | -0.532x | +29.85% |
| 1998-12-31 | $8.30 Million | $-6.30 Million | -0.759x | -- |
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA s… Read more